EE03688B1 - N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks - Google Patents

N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks

Info

Publication number
EE03688B1
EE03688B1 EE9800437A EE9800437A EE03688B1 EE 03688 B1 EE03688 B1 EE 03688B1 EE 9800437 A EE9800437 A EE 9800437A EE 9800437 A EE9800437 A EE 9800437A EE 03688 B1 EE03688 B1 EE 03688B1
Authority
EE
Estonia
Prior art keywords
preparation
heteroarylamines
heteroarylmethyl
phenyl
pharmaceutical composition
Prior art date
Application number
EE9800437A
Other languages
English (en)
Estonian (et)
Other versions
EE9800437A (et
Inventor
Gaston Venet Marc
Charles Sanz G�rard
Jean-Pierre Mabire Dominique
Fernand Armand Lacrampe Jean
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE9800437A publication Critical patent/EE9800437A/xx
Publication of EE03688B1 publication Critical patent/EE03688B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EE9800437A 1996-06-27 1997-06-19 N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks EE03688B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201781 1996-06-27
PCT/EP1997/003248 WO1997049704A1 (en) 1996-06-27 1997-06-19 N-[4-(heteroarylmethyl)phenyl]-heteroarylamines

Publications (2)

Publication Number Publication Date
EE9800437A EE9800437A (et) 1999-06-15
EE03688B1 true EE03688B1 (et) 2002-04-15

Family

ID=8224119

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800437A EE03688B1 (et) 1996-06-27 1997-06-19 N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks

Country Status (32)

Country Link
US (5) US6124330A (cs)
EP (1) EP0907650B1 (cs)
JP (1) JP3404749B2 (cs)
KR (1) KR100365312B1 (cs)
CN (1) CN1102593C (cs)
AR (1) AR007626A1 (cs)
AT (1) ATE229019T1 (cs)
AU (1) AU711575B2 (cs)
BG (1) BG63545B1 (cs)
BR (1) BR9710002A (cs)
CA (1) CA2258165C (cs)
CZ (1) CZ297769B6 (cs)
DE (1) DE69717627T2 (cs)
DK (1) DK0907650T3 (cs)
EE (1) EE03688B1 (cs)
ES (1) ES2188957T3 (cs)
HU (1) HU223093B1 (cs)
ID (1) ID17275A (cs)
IL (1) IL127740A (cs)
MY (1) MY116917A (cs)
NO (1) NO312102B1 (cs)
NZ (1) NZ333382A (cs)
PL (1) PL201704B1 (cs)
PT (1) PT907650E (cs)
RU (1) RU2190611C2 (cs)
SI (1) SI0907650T1 (cs)
SK (1) SK282769B6 (cs)
TR (1) TR199802709T2 (cs)
TW (1) TW490464B (cs)
UA (1) UA53649C2 (cs)
WO (1) WO1997049704A1 (cs)
ZA (1) ZA975698B (cs)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ333382A (en) * 1996-06-27 2000-05-26 Janssen Pharmaceutica Nv N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
CA2312720A1 (en) 1997-12-11 1999-06-17 Janssen-Cilag S.A. Retinoic acid mimetic anilides
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE19951701A1 (de) 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Imidazolyl-substituierten Carbinolen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
AU2003223672A1 (en) * 2002-04-17 2003-11-03 Tyco Healthcare Group Lp Method and apparatus for anastomosis including an expandable anchor
WO2004041162A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Inhibitors of akt activity
AU2004233827B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
KR101218213B1 (ko) * 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
DE10337942A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
CA2581579A1 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
BRPI0516025A (pt) * 2004-09-24 2008-08-19 Allergan Sales Inc 4-(heteroaril-metil e heteroaril-metil substituìda)-imidazol-2-tionas que atuam como agonistas alfa2 adrenérgicos
KR20070063016A (ko) * 2004-09-24 2007-06-18 알러간, 인코포레이티드 알파2 아드레날린성 아고니스트로서 작용하는 4-(축합시클릭메틸)-이미다졸-2-티온
AU2005290013A1 (en) * 2004-09-28 2006-04-06 Allergan, Inc. Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN101400261B (zh) * 2006-01-17 2013-07-10 斯蒂菲尔实验室公司 使用三唑化合物治疗炎症异常
AU2007311026B2 (en) * 2006-10-17 2012-05-17 Stiefel Laboratories, Inc. Talarazole metabolites
PT2201006E (pt) * 2007-10-18 2011-05-05 Domp S P A Derivados de (r)-4-(heteroaril)-feniletilo e composi??es farmac?uticas que os cont?m
GB0811091D0 (en) * 2008-06-17 2008-07-23 Cancer Rec Tech Ltd CYP26 Inhibitors
CA2800664C (en) 2010-06-01 2019-09-24 Angion Biomedica Corp. Benzothiazole cytochrome p450 inhibitors and therapeutic uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
KR101108577B1 (ko) * 2010-07-28 2012-01-30 국제엘렉트릭코리아 주식회사 테이프 히터
RU2632900C2 (ru) 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение
WO2013028771A1 (en) 2011-08-23 2013-02-28 Leong Hwei Xian Reversing intestinal inflammation by inhibiting retinoic acid metabolism
DK3180335T3 (da) 2014-08-11 2021-08-09 Angion Biomedica Corp Cytokrom-p450-inhibitorer og anvendelser deraf
CN107531631B (zh) 2014-12-31 2021-09-03 安吉昂生物医药公司 用于治疗疾病的方法和药剂
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
CN106632051A (zh) * 2016-12-15 2017-05-10 青岛辰达生物科技有限公司 一种盐酸右美托咪定中间体的合成方法
CN106588780A (zh) * 2016-12-15 2017-04-26 青岛辰达生物科技有限公司 一种盐酸右美托咪定中间体的制备工艺
CN106588779A (zh) * 2016-12-15 2017-04-26 青岛辰达生物科技有限公司 一种合成盐酸右美托咪定中间体的方法
KR20210055340A (ko) 2019-11-07 2021-05-17 정화종 화물 커버
CN115462347B (zh) * 2021-08-13 2024-07-16 广州市妇女儿童医疗中心 视黄酸代谢通路在先天性巨结肠疾病中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002073A1 (en) * 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
HU208124B (en) 1990-04-25 1993-08-30 Nissan Chemical Ind Ltd Process for producing pyridazinone derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
ZW1992A1 (en) * 1991-02-25 1993-09-22 Janssen Pharmaceutica Nv 4-/(2-benzotiazolyl)methylamino/-b-/(3,4-difluorephenoxy)methyl/-1-piperidine ethanol
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
TW282469B (cs) * 1993-06-11 1996-08-01 Janssen Pharmaceutica Nv
TW321649B (cs) 1994-11-12 1997-12-01 Zeneca Ltd
US5582832A (en) * 1995-06-06 1996-12-10 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Compositions for topical application to skin
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SI0880508T1 (en) 1996-02-13 2003-10-31 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
NZ333382A (en) * 1996-06-27 2000-05-26 Janssen Pharmaceutica Nv N-[4-(heteroarylmethyl)phenyl]-heteroarylamines

Also Published As

Publication number Publication date
NO986017L (no) 1999-02-19
HU223093B1 (hu) 2004-03-29
US20030176419A1 (en) 2003-09-18
EE9800437A (et) 1999-06-15
KR100365312B1 (ko) 2003-03-06
NZ333382A (en) 2000-05-26
HK1018458A1 (en) 1999-12-24
US6124330A (en) 2000-09-26
TW490464B (en) 2002-06-11
JP3404749B2 (ja) 2003-05-12
ID17275A (id) 1997-12-18
ES2188957T3 (es) 2003-07-01
CZ423198A3 (cs) 1999-05-12
RU2190611C2 (ru) 2002-10-10
BG103013A (en) 1999-09-30
AU711575B2 (en) 1999-10-14
EP0907650A1 (en) 1999-04-14
SI0907650T1 (en) 2003-06-30
HUP9902138A2 (hu) 1999-10-28
CA2258165A1 (en) 1997-12-31
SK282769B6 (sk) 2002-12-03
PL201704B1 (pl) 2009-04-30
UA53649C2 (uk) 2003-02-17
WO1997049704A1 (en) 1997-12-31
US7205312B2 (en) 2007-04-17
CA2258165C (en) 2009-03-03
NO312102B1 (no) 2002-03-18
EP0907650B1 (en) 2002-12-04
NO986017D0 (no) 1998-12-21
CZ297769B6 (cs) 2007-03-28
US7378433B2 (en) 2008-05-27
TR199802709T2 (xx) 1999-02-22
SK178198A3 (en) 2000-05-16
BG63545B1 (bg) 2002-04-30
US6486187B1 (en) 2002-11-26
PT907650E (pt) 2003-04-30
JP2000503670A (ja) 2000-03-28
US6833375B2 (en) 2004-12-21
CN1223654A (zh) 1999-07-21
US20050113378A1 (en) 2005-05-26
MY116917A (en) 2004-04-30
AR007626A1 (es) 1999-11-10
IL127740A (en) 2001-09-13
IL127740A0 (en) 1999-10-28
ATE229019T1 (de) 2002-12-15
PL330816A1 (en) 1999-06-07
ZA975698B (en) 1999-01-20
AU3435697A (en) 1998-01-14
BR9710002A (pt) 1999-08-10
DE69717627D1 (de) 2003-01-16
KR20000016196A (ko) 2000-03-25
DE69717627T2 (de) 2003-09-18
HUP9902138A3 (en) 2001-10-29
CN1102593C (zh) 2003-03-05
DK0907650T3 (da) 2003-03-10
US20070088062A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
EE03688B1 (et) N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks
EE9800136A (et) Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
DK0799052T3 (da) Ny antihrombotisk formulering, fremgangsmåde til dens fremstilling og anvendelse deraf
EE9900018A (et) Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
EE200300236A (et) 1,2-difenüülasetidinoonid, nende kasutamine, ravim ja selle valmistamismeetod
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE200000596A (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod
FI951468A7 (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
FI962908L (fi) Mikrobinvastainen koostumus, sen valmistusmenetelmä ja sen käyttö
KR100547921B1 (ko) 설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
FI971861A7 (fi) Puristuskoostumus, valmistusmenetelmä, puristusmenetelmä ja puristustu otteita
EE04717B1 (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
EE9800200A (et) Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04087B1 (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
FI944182A7 (fi) Yhtenäiskiteitä sisältävä koostumus, menetelmä sen valmistamiseksi ja sen käyttö
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
FI972988L (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
EE04770B1 (et) Tritsüklilised delta3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE04260B1 (et) Farmatseutiline kompositsioon, selle valmistamisemeetod ja kasutamine

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231